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Idiopathic infantile nystagmus (IIN) is an inherited disorder in which the nystagmus arises independently of any other symptoms,
leading to the speculation that the disorder represents a primary defect in the area of the brain responsible for ocular motor
control. The inheritance patterns are heterogeneous, however the most common form is X-linked. FRMD7 resides at Xq26-27 and
approximately 50% of X-linked IIN families map to this region. Currently 45 mutations within FRMD7 have been associated with
IIN, conﬁrming the importance of FRMD7 in the pathogenesis of the disease. Although mutations in FRMD7 are known to cause
IIN, very little is known about the function of the protein. FRMD7 contains a conserved N-terminal FERM domain suggesting
that it may provide a link between the plasma membrane and actin cytoskeleton. Limited studies together with the knowledge
of the function of other FERM domain containing proteins, suggest that FRMD7 may play a role in membrane extension during
neuronal development through remodeling of the actin cytoskeleton.
1.IdiopathicInfantileNystagmus
Nystagmus consists of rhythmic involuntary oscillations
of the eyes and can occur in early childhood (infantile
nystagmus) or can be acquired later in life (acquired
nystagmus) [1, 2]. Idiopathic infantile nystagmus (IIN) has
been found to be the most common type of nystagmus
and has an estimated prevalence of 1.9 per 10,000 in
Leicestershire and Rutland, UK [1]. Unlike other forms of
nystagmus, IIN arises independently of any other visual or
neurologicalabnormality.Thishasledtothespeculationthat
the disorder represents a primary defect in regions of the
brain responsible forocular motor control[3,4].Theimpact
of nystagmus on vision varies but can be signiﬁcant due to
the constant eye movement. Indeed visual function in many
patients scores worse than in those with age-related macular
degeneration [5].
2. Geneticsof IIN
The inheritance patterns of IIN are heterogeneous and have
been described as autosomal dominant (OMIM 164100)
[6–8], autosomal recessive (OMIM 257400) [9]a n dX -
linked (OMIM 31700). However, the most common form of
inheritance is X-linked [10], which can be either dominant
or recessive and X-linked loci have been identiﬁed at
Xp11.4-p11.3 [11], Xp22 [12], and Xq26-q27 [10]. The
gene responsible for IIN at the Xp11.4-p11.3 locus has not
yet been identiﬁed. GPR143 resides at Xp22 and mutations
within it are primarily linked to ocular albinism (OA), where
nystagmus results as a secondary phenotype [12]. However,
GPR143 mutations have also been found to cause a variant
form of OA with IIN as the most prominent and only
consistentﬁnding[13]andhasbeenreportedinIINfamilies,
without the classical phenotype of ocular albinism [14].
This raises the possibility that GPR143 mutations may be
more directly involved in the pathogenesis of IIN than ﬁrst
thought. However, albinism must be excluded as a factor
by extensive clinical examination before it can be conﬁrmed
that Xp22 is an IIN locus. In approximately 50% of families,
X-linked IIN maps to Xq26-q27 and has been shown to
be linked to mutations in the FRMD7 gene [4, 15, 16]. X-
linked nystagmus pedigrees linked to the FRMD7 locus have2 Journal of Ophthalmology
showneitherdominantorrecessiveinheritancepatternswith
a variable degree of penetrance in females [16, 17]. Possible
mechanisms for the variability in penetrance include skewed
X-inactivation, genetic modiﬁers (such as polymorphisms
in interacting proteins), and other nongenetic inﬂuences on
oculomotor development. These factors may also explain
why both dominant and recessive X-linked pedigrees can
show linkage to the same region [16].
WhilstskewedX-inactivationisapossiblemechanismfor
the variable penetrance seen amongst females, the evidence
for it remains controversial. Kaplan et al. demonstrated an
increased susceptibility to skewed X-inactivation in clini-
cally aﬀected females harboring FRMD7 mutations when
compared to their unaﬀected spouses [17], whilst Self et
al. did not ﬁnd a clear-cut diﬀerence in the pattern of X-
inactivation between aﬀected and unaﬀected carriers of the
FRMD7 mutations [16]. In agreement with Kaplan et al., the
vast majority of genes on the long arm of the X chromosome
are subject to X-inactivation, including those immediately
ﬂanking FRMD7 (MST4, MBNL3, and RAP2C) [16]. Since
genesthataresubjectedtoX-inactivationtendtobeclustered
into domains, it is very likely that FRMD7 is also inactivated.
If complete skewing is restricted to the speciﬁc cell lineages
such as parts of the developing brain and retina (where
most FRMD7 expression occurs), it is possible that complete
skewing may be missed using DNA extracted from blood or
saliva [16]. Currently, the basis of incomplete penetrance of
the disease in females is not explained.
3. FRMD7 (FERMDomain-Containing7)
DomainStructure
The human FRMD7 gene (ENSG000001656940) comprises
12 exons (ENST00000298542) and encodes a 714-resi-
due polypeptide (ENSP00000298542). FRMD7 contains a
conserved N-terminal FERM domain and FERM-adjacent
domain, whereas the C-terminal region bears no signiﬁcant
homology to other proteins (Figure 1). FERM domains are
characteristic of the band 4.1 superfamily and take their
name fromthe 4.1(fourpoint one) andERM(ezrin, radixin,
and moesin) proteins in which they were ﬁrst discovered
[18]. The FERM domain of FRMD7 is located between
amino acids 2–282 (ensemble, ENSP00000298542), whilst
the FA domain is located between amino acids 288–336
(ensemble, ENSP00000298542) (Figure 1). FERM domains
have 3 lobed “cloverleaf” structures, each lobe representing
a compactly folded structure. Lobe A (also known as F1,
the most N-terminal) has a fold resembling ubiquitin;
lobe B (also known as F2, the central lobe) resembles
acyl-CoA-binding proteins and lobe C (also known as F3,
the most C-terminal) has a fold related to a pleckstrin
homology domain/phosphotyrosine binding domain. The
close packing of these domains suggests they do not function
independently, but rather form a coordinated structure [19].
Ezrin, radixin, and moesin are a family of proteins that
provide a link between the plasma membrane and the
cortical actin cytoskeleton [20]. This suggests that FRMD7
may be involved in signal transduction between the plasma
membrane and cytoskeleton. The FA region is found next
to FERM domains in a subset of FERM containing proteins.
This region is thought to be a regulatory adaption in
these proteins, as it contains conserved motifs that are
potential substrates for kinases and is the known regulatory
phosphorylation site of 4.1 [19]. FARP1 and FARP2 are the
closest homologues of FRMD7 [4]. As both of these proteins
play roles during neuronal development [21–23], it has been
suggested that FRMD7 may also regulate this process.
4. Mutationof FRMD7 Is AssociatedwithIIN
To date, 45 diﬀerent mutations within FRMD7 have been
reported in IIN patients (Table 1), 79% of which are unique
and have only been identiﬁed in one IIN family. The muta-
tions c.284+1G>A, c.425T>G (p.L142R), and c.1003C>T
(p.R335X) are the most common and have each been
detected in 3 diﬀerent families. The mutations concentrate
heavily within the FERM and FA domains, suggesting that
these domains play important roles in the function of
FRMD7.
Just under half (42%) of the mutations identiﬁed within
FRMD7 are predicted to cause gross defects at the protein
level due to introduction of frameshift, nonsense mutations,
and/or aberrant splicing. The latter may also lead to
nonsense-mediated decay of the mRNA. When the noncon-
served splice site mutation c.162+5G>A was investigated,
negligible amounts of transcript were detected compared
with controls [4]. In contrast, the apparently silent variant,
G252A (V84V), creates a new splice acceptor site within
exon 4 that in lymphocytes results in the loss of transcript
containing the sequence of exons 1–5 and the rare presence
of a transcript with skipping of exon 4 [4].
The other half (53%) of the mutations identiﬁed within
FRMD7 are missense. These mutations may disrupt FRMD7
function by destabilizing the protein, disrupting binding
sites with interacting partners and/or preventing regulatory
modiﬁcations to the protein such as phosphorylation and/or
glycosylation. When the eﬀects of the mutations p.G24R,
p.L142R, p.A266P, and p.C271Y were modelled by Tarpey
et al. on the three-dimensional structure of the cytoskeletal
protein 4.1R (the closest homologue of FRMD7 with known
structure), they found that the missense mutations p.G24R,
p.L142R, and p.C271Y are likely to destabilize the protein by
the introduction of larger amino acids within restricted areas
of the protein. It was also predicted that the introduction of
a proline residue at position 266 (p.A266P) might disrupt
a helical region in the F3 lobe of the FERM domain [4].
Similarly, the histidine at codon 208 is one of two amino
acids located inside the region between two β-sheets, and
substituting it with an arginine is likely to destabilize the
proteinbyintroducingalargeraminoacidwithinarestricted
area of the protein [24]. However, these predictions have yet
to be veriﬁed experimentally.
In addition to the mutations listed in Table 1, a large
intragenic deletion of FRMD7 that spans exons 2, 3, and 4
has been reported in a pedigree with 2 separate X-linked
traits, idiopathic infantile nystagmus, and deuteranomaly.Journal of Ophthalmology 3
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Figure 1: A schematic representation of the structure of the FRMD7 protein. It contains an N-terminal FERM domain (green) and FERM-
adjacent (FA) domain (yellow). The FA domain consists of the 3 lobes F1 (lobe A), F2 (lobe B) and F3 (lobe C). The positions of IIN
mutations within FRMD7 have been indicated. Many of the mutations cluster around the F3 lobe of the FERM domain and the FA domain.
The FRMD7 mutation is associated with the family’s nys-
tagmus. It is hypothesised that this deletion eliminates 227
nucleotides of the FRMD7 gene causing a frame shift that
alters 19 amino acids before premature termination at codon
39. Further work sequencing the FRMD7 gene across the
mutated area (including coding and noncoding regions)
would need to be carried out in this family to conﬁrm the
exact location of the deletion.
5. FRMD7 mRNA Expressionin
theDevelopingBrain
Initially, Tarpey et al. employed conventional RT-PCR to
examine the expression pattern of FRMD7 in human adult
and fetal tissues (kidney, liver, pancreas, heart, and brain).
They found that FRMD7 is expressed in all adult tissues
examined; however, the levels of expression were lower in
the heart and brain. In the human fetal tissues examined,
FRMD7 mRNA was only detected in kidney [4]. This
suggests that FRMD7 is only expressed in the fetal kidney.
However, in the same study, a further investigation using in
situ hybridization revealed that FRMD7 mRNA is expressed
in human embryonic brain at days 37 and 56 postovulation
[4]. In addition, a study by Self et al., which investigated
the expression of FRMD7 mRNA in murine heart lung and
brain during early development stages (ED11-PD8) using
real-time PCR analysis, has shown that FRMD7 is expressed
in these tissues [32]. It is likely that Tarpey et al. missed
FRMD7 mRNA expression in human fetal heart and brain
when they employed the less sensitive technique of RT-PCR.
This hypothesis is supported by data from Self et al., which
shows that in murine heart and lung (but not brain) FRMD7
mRNA expression is low (at limits of detection) during
the early developmental stages (ED11-PD8) and increases
signiﬁcantly in adulthood [32].
Interestingly, Self et al. found that the expression proﬁle
of FRMD7 mRNA during early development (ED11-PD8)
is diﬀerent in murine brain samples compared to heart
and lung. In the brain, FRMD7 mRNA expression was
similarly low at early time points (ED11–17); however,
there was a marked increase in the expression at ED18. A
higher level of expression was maintained until adulthood
(PD1, PD8, and adulthood) [32]. Embryonic mouse brain
development starts approximately 10-11 days after gestation
(ED10-ED11).Byembryonicday18(ED18),neuronsstartto
sendoutaxonsanddendritespoisedforsynapticconnections
[33]. The approximate 5-fold increase of FRMD7 mRNA at
ED18 suggests that it is involved in this process [32]. Further
to this, when Matsuki et al. examined the expression proﬁles
of 397 genes related to neuronal development in ED12,
15, 18, and postnatal day 0 mouse brains, they found that
expression of 14.9% of the genes peaked at ED18. The genes
that peaked at ED18 have functions related to survival and
growth, synapse formation and function, and determination
and diﬀerentiation [34]. As FRMD7 has a similar temporal
expression to this set of genes, it suggests that FRMD7 may
also play a role in these processes.
In addition to determining that FRMD7 mRNA is
expressed in human embryonic brain at 37 and 56 days
postovulation, Tarpey et al. employed in situ hybridization
to reveal that its expression is restricted and localized to
certain areas. At 56 days postovulation, FRMD7 expression
was seen in the ventricular layer of the forebrain, midbrain,
cerebellar primordium, spinal cord, and developing neural
retina [4]. In contrast, at 37 days postovulation, expression
was restricted to the mid- and hindbrain [4]. These regions
areknowntobeinvolvedinmotorcontrolofeyemovements,
suggesting that FRMD7 may be involved in this process.
As FRMD7 shows high sequence homology to FARP2 [4],
which is involved in neuronal development [21, 35], it has
been speculated that FRMD7 may be involved in neuronal
development in these regions of the brain [4].
Following on from this study, a more detailed exami-
nation of FRMD7 mRNA expression in the cerebral cortex4 Journal of Ophthalmology
Table 1: A list of the FRMD7 mutations associated with idiopathic infantile nystagmus (IIN). Del: deletion, Ins: insertion, T: truncation, N:
nonsense, M: missense, and S: splice.
Mutation Class Exon/intron aﬀected Reference
DNA Protein
c.41 43delAGA p.K14del del Exon 1 [25]
[4]
c.47T>C p.F16S M Exon 1 [37]
c.57+5G>AS I n t r o n 1 [ 15]
c.58-1G>AS I n t r o n 1 [ 37]
c.58C>T p.Q20X N/T Exon 2 [15]
c.70G>A p.G24R M Exon 2 [25]
[4]
c.70G>T p.G24W M Exon 2 [26]
c.71G>A p.G24E M Exon 2 [4]
c.162+5G>AS I n t r o n 2 [ 4]
c.205+2T>GS I n t r o n 3 [ 4]
c.252G>A p.V84V S Exon 4 [4]
c.284+1G>AS I n t r o n 4 [4]
[16]
c.425T>G p.L142R M Exon 6 [27]
[4]
c.436C>T p.R146W M Exon 6 [25]
c.479 480insT p.F161LfsX172 Ins/T Exon 6 [4]
c.498-2A>GS I n t r o n 6 [ 15]
c.601C>T p.Q201X N/T Exon 7 [4]
c.623A>G p.H208R M Exon 7 [24]
c.645+1G>CS I n t r o n 7 [ 4]
c.661A>G p.N221D M Exon 8 [4]
c.673T>G p.W225G M Exon 8 [15]
c.676G>A p.A226T M Exon 8 [4]
c.685C>T p.R229C M Exon 8 [25]
c.685C>G p.R229G M Exon 8 [17]
c.691T>G p.L231V M Exon 8 [4]
c.694 695delAG p.S232FfsX233 del/T Exon 8 [26]
c.781C>G p.R261G M Exon 9 [28]
c.782G>A p.R260Q M Exon 9 [26]
c.796G>C p.A266P M Exon 9 [4]
c.811T>A p.C271S M Exon 9 [37]
c.812G>T p.C271F M Exon 9 [26]
[29]
c.812G>A p.C271Y M Exon 9 [4]
c.814G>T p.V272L M Exon 9 [30]
c.824A>C p.H275P M Exon 9 [15]
c.880 881insA p.S294KfsX302 Ins/T Exon 9 [16]
c.886G>C p.G296R M Exon 9 [28]
c.887delG p.G296VfsX318 del/T Exon 9 [4]
c.902A>G p.Y301C M Exon 9 [4]
c.910C>T p.R303X N/T Exon 10 [26]
c.1003C>T p.R335X N/T Exon 11 [4]
[28]
c.1019C>T p.S340L M Exon 11 [4]
c.1050+1G>AS I n t r o n 1 1 [ 4]
c.1262delC p.P421LfsX443 del/T Exon 12 [4]
c.1275 1276delTG p.E426AfsX429 del/T Exon 12 [31]Journal of Ophthalmology 5
duringhumanembryodevelopment(CarnegieStage(CS)15,
CS16, CS19, CS22, and CS23) and human fetal development
(9 weeks postconception (wpc) and 14 wpc) by in situ
hybridization was undertaken [3]. Strong hybridization
signals were observed in the ventricular zone (VZ) of the
forebrain at CS16 and CS19, in both the telencephalon and
diencephalon. At CS22 and CS23, FRMD7 mRNA, remained
expressed in the VZ, but it was also observed in the interme-
diate zone and cortical plate. By 9 and 14 wpc, limited cells
in the ventricular layer showed expression of FRMD7 mRNA
whilst the majority of FRMD7 expression was observed in
thecorticalplateandsubplate[3].Duringearlydevelopment
of the brain (prenatally) immature neurons generated from
the ﬁnal mitotic division of the neuronal cell progenitors
begin to migrate from the VZ to the cortical plate using
processes of radial glial cells as a guide [36]. These data
suggest that FRMD7 may play a role in the radial migration
of newborn neurons in the cerebral cortex during human
embryo development.
In a recent study, we identiﬁed expression of FRMD7
mRNA within speciﬁc neural substrates such as the devel-
oping aﬀerent and eﬀerent arms of vestibulo-ocular and
optokinetic reﬂex. In addition, an interesting expression
pattern was observed within the developing cerebellum
(rhombomere 1) and the VZ of rhombomeres 2, 3, and 4
which would give rise to the vestibular nuclei (the horizon-
tal neural integrator site) [37]. These expression patterns
correlate well to the phenotype observed. For instance, we
identiﬁed that FRMD7 mutations are causative of familial
periodic alternating nystagmus and in aﬀected patients the
optokinetic reﬂex was absent [37]. Similarly, in unaﬀected
carriers with FRMD7 mutations, a subnormal gain was
observed for the optokinetic reﬂex [37].
6. FRMD7 ProteinExpressionin
theDevelopingBrain
In keeping with the mRNA expression data, immunohisto-
chemical analysis of the developing mouse cerebral cortex
revealed that there was strong immunoreactivity of FRMD7
protein in the ventricular and intermediate zones at early
stages of development (ED13 and ED15), whereas at later
developmentstages(ED17andP0),itappearstoberestricted
to the cortical plate [3]. High levels of FRMD7 protein have
also been detected in the brainstem (pons, medulla, and
oblongata) in the human fetal brain at 16-17 wpc, indicating
that its expression is not restricted to the cortex [38]. This
area of the brain is also an important region associated with
ocular motor control.
When the expression of FRMD7 protein in early post-
natal tissues was investigated by Betts-Henderson et al. they
foundthatitishighlyexpressedineyeandbrain(cortex,hip-
pocampus,cerebellum,andolfactorybulb).Incontrast,little
or no expression was observed in the liver, kidney, skeletal
muscle, and heart muscle [3]. It is, therefore, speculated that
FRMD7 may also play a role in the adapting postnatal brain
and eye. The brain tissues examined in this study consisted
of many cell types including glial cells and neurons. FRMD7
is expressed in cultured cortical neurons and its expression
level increases at later times in culture. The upregulation of
FRMD7 at later passages suggests that it may play a role in
thematurationandmorphologicaldiﬀerentiationofneurons
[3]. In agreement with this hypothesis, FRMD7 mRNA levels
are rapidly and signiﬁcantly increased (P = 0.0008, 12
hours post diﬀerentiation) in diﬀerentiating Neuro2A cells
when compared with undiﬀerentiated cells [3]. Moreover,
an increase in FRMD7 protein expression was also observed
within 12 hours of diﬀerentiation [3].
7. FRMD7 Promotes Neurite Elongation and
MayRegulateNeuronalActin Dynamicsat
the Growth Cone
FRMD7 protein is highly colocalised with actin within
the cell body of both undiﬀerentiated and diﬀerentiated
Neuro2A cells. In addition, in diﬀerentiated Neuro2A cells,
FRMD7 is observed in the neurite processes and growth
cones. FRMD7 is highly localized to the actin-rich regions
of the primary neurite extension but is almost absent from
the actin-rich secondary extensions arising from the primary
neurite.Withingrowthcones,FRMD7ispresentattheactin-
rich distal end [3]. The C-terminus of FRMD7 has been
shown to play a key role in the subcellular localization of
FRMD7 in Neuro2A cells as mutant proteins lacking the C-
terminal domain or containing the c.1003C>T (p.R335X)
mutation exhibited a primarily nuclear distribution [38].
Knockdown of FRMD7 protein expression in nondiﬀer-
entiatedNeuro2Acellsresultsinanincreaseinthenumberof
cells with neurites, in the average number of neurites per cell
and in the percentage of cells with neurite branching. The
same is true in diﬀerentiated Neuro2A cells; however, these
cells also exhibit a large reduction in average neurite length.
These data further suggest FRMD7 plays an important
role during neuronal development, speciﬁcally elongation of
axons and dendrites [3].
Neurite formation, branching and elongation all require
spatial and dynamic reorganisation of the cytoskeleton.
If FRMD7 regulates these processes, it must be able to
coordinate remodeling of the actin cytoskeleton. Indeed the
absence of FRMD7 in diﬀerentiated Neuro2A cells results in
a noticeable increase in F-actin [3]. This increase in poly-
merized actin is reﬂected by an increased number of neuritis
per cell as well as increased ﬁlopodia and lamellipodia in the
neurite processes.
FRMD7 protein is expressed at the actin-rich distal ends
of growth cones, and it promotes the elongation of neuritis,
suggesting that it may regulate growth cone guidance. One of
the most crucial steps in the formation and movement of the
neuronal growth cone is the recruitment and activation of
the Rho family of small GTPases (Rac1, Cdc42, and RhoA)
and their regulators, the Rho guanine nucleotide exchange
factors (GEF) and GTPases activating proteins (GAP) [39].
This is because the Rho GTPases are key regulators of actin
cytoskeleton dynamics [40]. It remains to be determined
whether FRMD7, like FARP1 and FARP2, functions as a GEF
[21–23]. However, the FERM domain-containing protein
radixin is known to be an upstream regulator of Rho6 Journal of Ophthalmology
family members, interacting with both inhibitory regulators
(e.g., Rho GDI) and stimulatory regulators (e.g., Dbl) [41].
Therefore, it is possible that FRMD7 is involved in the
regulation of neuronal cytoskeletal dynamics through Rho
GTPase signaling at the growth cone [3].
8. Summary
Currently, 45 mutations in FRMD7 have been associated
with IIN almost all concentrate in the conserved FERM and
FA domain. Although very little is known about FRMD7
function, expression analysis and known functions of related
proteins suggest that it may carry out roles related to neu-
ronal development. Currently, FRMD7 is thought to partic-
ipate in pathways that control survival and growth, synapse
formation and function, determination and diﬀerentiation
(axogenesis and dendritogenesis), asymmetrical neuronal
precursor cell division, and the radial migration of newborn
neurons. More speciﬁcally, it is thought that FRMD7 is
involved in the regulation of neuronal cytoskeletal dynamics
atthegrowthconethroughRhoGTPasesignaling.Mutations
inFRMD7maypreventtherecruitmentandtheactivationof
the Rho family of small GTPases (Rac1, Cdc42, and RhoA)
and their regulators, the Rho GEFs and GAPs. In a similar
fashion to knockdown of FRMD7 expression, mutation of
FRMD7 in IIN may prevent elongation of neurite processes
during diﬀerentiation. In addition, mutations in FRMD7
may prevent axons from changing direction in response
to stimuli. Nystagmus may, therefore, result from defective
axogenesis, dendritogenesis, and neuronal guidance in the
areas of the brain which control eye movements.
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